These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38924406)

  • 21. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
    Lee CY; Menozzi E; Chau KY; Schapira AHV
    J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease.
    Marano M; Zizzo C; Malaguti MC; Bacchin R; Cavallieri F; De Micco R; Spagnolo F; Bentivoglio AR; Schirinzi T; Bovenzi R; Ramat S; Erro R; Sorrentino C; Sucapane P; Pilotto A; Lupini A; Magliozzi A; Di Vico I; Carecchio M; Bonato G; Cilia R; Colucci F; Tamma F; Caputo E; Mostile G; Arabia G; Modugno N; Zibetti M; Ceravolo MG; Tambasco N; Cossu G; Valzania F; Manganotti P; Di Lazzaro V; Zappia M; Fabbrini G; Tinazzi M; Tessitore A; Duro G; Di Fonzo A
    Parkinsonism Relat Disord; 2024 Jul; 124():107023. PubMed ID: 38843618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.
    Sanyal A; DeAndrade MP; Novis HS; Lin S; Chang J; Lengacher N; Tomlinson JJ; Tansey MG; LaVoie MJ
    Mov Disord; 2020 May; 35(5):760-773. PubMed ID: 32034799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.
    Toffoli M; Smith L; Schapira AHV
    J Neurochem; 2020 Jul; 154(1):11-24. PubMed ID: 31965564
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Skrahin A; Horowitz M; Istaiti M; Skrahina V; Lukas J; Yahalom G; Cohen ME; Revel-Vilk S; Goker-Alpan O; Becker-Cohen M; Hassin-Baer S; Svenningsson P; Rolfs A; Zimran A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000225
    [No Abstract]   [Full Text] [Related]  

  • 27. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GBA1 and The Immune System: A Potential Role in Parkinson's Disease?
    Al-Azzawi ZAM; Arfaie S; Gan-Or Z
    J Parkinsons Dis; 2022; 12(s1):S53-S64. PubMed ID: 36057834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
    den Heijer JM; Cullen VC; Quadri M; Schmitz A; Hilt DC; Lansbury P; Berendse HW; van de Berg WDJ; de Bie RMA; Boertien JM; Boon AJW; Contarino MF; van Hilten JJ; Hoff JI; van Mierlo T; Munts AG; van der Plas AA; Ponsen MM; Baas F; Majoor-Krakauer D; Bonifati V; van Laar T; Groeneveld GJ
    Mov Disord; 2020 Sep; 35(9):1667-1674. PubMed ID: 32618053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Blauwendraat C; Tayebi N; Woo EG; Lopez G; Fierro L; Toffoli M; Limbachiya N; Hughes D; Pitz V; Patel D; Vitale D; Koretsky MJ; Hernandez D; Real R; Alcalay RN; Nalls MA; Morris HR; Schapira AHV; Balwani M; Sidransky E
    Mov Disord; 2023 May; 38(5):899-903. PubMed ID: 36869417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death.
    Keatinge M; Bui H; Menke A; Chen YC; Sokol AM; Bai Q; Ellett F; Da Costa M; Burke D; Gegg M; Trollope L; Payne T; McTighe A; Mortiboys H; de Jager S; Nuthall H; Kuo MS; Fleming A; Schapira AH; Renshaw SA; Highley JR; Chacinska A; Panula P; Burton EA; O'Neill MJ; Bandmann O
    Hum Mol Genet; 2015 Dec; 24(23):6640-52. PubMed ID: 26376862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.
    Gregorio I; Russo L; Torretta E; Barbacini P; Contarini G; Pacinelli G; Bizzotto D; Moriggi M; Braghetta P; Papaleo F; Gelfi C; Moro E; Cescon M
    Mol Neurodegener; 2024 Mar; 19(1):22. PubMed ID: 38454456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
    Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
    J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
    Menozzi E; Toffoli M; Schapira AHV
    Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucocerebrosidase as a therapeutic target for Parkinson's disease.
    Chen Y; Sam R; Sharma P; Chen L; Do J; Sidransky E
    Expert Opin Ther Targets; 2020 Apr; 24(4):287-294. PubMed ID: 32106725
    [No Abstract]   [Full Text] [Related]  

  • 38. GBA1-associated parkinsonism: new insights and therapeutic opportunities.
    Ryan E; Seehra G; Sharma P; Sidransky E
    Curr Opin Neurol; 2019 Aug; 32(4):589-596. PubMed ID: 31188151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High level transcription of the glucocerebrosidase pseudogene in normal subjects and patients with Gaucher disease.
    Sorge J; Gross E; West C; Beutler E
    J Clin Invest; 1990 Oct; 86(4):1137-41. PubMed ID: 1698821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
    Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
    Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.